Einzeltreffer — DigiBib

Osteonecrosis is a harmful musculoskeletal disease. We aim to detect the effects of icariin (ICA) in MC3T3-E1 cell. MC3T3-E1 cell was pretreated with ICA and was subjected to hypoxia stimuli. The tumor-associated long noncoding RNA expressed on chromosome 2 (TALNEC2) overexpression or silencing vectors (pTALNEC2 or si-TALNEC2) was utilized for MC3T3-E1 cell transfection. Viability and apoptosis rate were individually tested by cell counting kit-8 and Annexin V-fluorescein isothiocyanate/propidium iodide kit untied with flow cytometry. The alkaline phosphatase activity (ALP) activity was tested through ALP assay. The quantitative reverse transcription PCR or Western blot was performed for elements detection at the RNA or protein level. Hypoxia treatment induced viability inhibition and CyclinD1 reduction, but elevation of p53 and p16. It also promoted apoptosis by increasing apoptotic cells, Bax, and cleaved-poly ADP-ribose polymerase but decreasing Bcl-2. Also, hypoxia stimuli restrained ALP activity, and osteopontin, osteocalcin, and Runt-related transcription factor 2 expression. Those effects caused by hypoxia stimuli were all reversed by ICA. TALNEC2 was downregulated by ICA, whose impacts were subsequently abolished by pTALNEC2. Silencing TALNEC2 displayed similar effects with ICA. But the apoptosis was not affected by si-TALNEC2. ICA blocked ste20-related proline/alanine-rich kinase/c-Jun N-terminal kinase (SPAK/JNK) but triggered phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in MC3T3-E1 cell by suppressing TALNEC2. ICA relieved hypoxia-stimulated damage by restraining TALNEC2 through blocking SPAK/JNK and triggering PI3K/AKT/mTOR in the MC3T3-E1 cell.

Titel:	Icariin alleviates hypoxia-induced damage in MC3T3-E1 cells by downregulating TALNEC2.
Autor/in / Beteiligte Person:	Wang, W ; Xin, J ; Chen, W ; Jing, L ; Zhang, P
Link:	Zum Volltext
Zeitschrift:	Biotechnology and applied biochemistry, Jg. 67 (2020-11-01), Heft 6, S. 1000-1010
Veröffentlichung:	Jan. 2011- : Malden : Wiley-Blackwell ; <i>Original Publication</i>: San Diego : Academic Press, [cl986]-, 2020
Medientyp:	academicJournal
ISSN:	1470-8744 (electronic)
DOI:	10.1002/bab.1874
Schlagwort:	Animals Cell Hypoxia drug effects Cell Line Cell Survival drug effects Cyclin D1 biosynthesis Cyclin-Dependent Kinase Inhibitor p16 biosynthesis Mice RNA, Long Noncoding genetics Tumor Suppressor Protein p53 biosynthesis Down-Regulation drug effects Flavonoids pharmacology RNA, Long Noncoding biosynthesis
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Biotechnol Appl Biochem] 2020 Nov; Vol. 67 (6), pp. 1000-1010. <i>Date of Electronic Publication: </i>2020 Feb 07. MeSH Terms: Down-Regulation / drug effects ; Flavonoids / pharmacology ; RNA, Long Noncoding / *biosynthesis ; Animals ; Cell Hypoxia / drug effects ; Cell Line ; Cell Survival / drug effects ; Cyclin D1 / biosynthesis ; Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis ; Mice ; RNA, Long Noncoding / genetics ; Tumor Suppressor Protein p53 / biosynthesis References: Wang, Z., Wang, D., Yang, D., Zhen, W., Zhang, J., Peng, S. (2018) Osteoporos. Int. 29, 535-544. ; Larson, E., Jones, L. C., Goodman, S. B., Koo, K. H., Cui, Q. (2018) Int. Orthop. 42, 1723-1728. ; Petek, D., Hannouche, D., Suva, D. (2019) EFORT Open Rev. 4, 85-97. ; Ikeuchi, K., Hasegawa, Y., Seki, T., Takegami, Y., Amano, T., Ishiguro, N. (2015) Mod. Rheumatol. 25, 278-281. ; Zhang, X., Liu, T., Huang, Y., Wismeijer, D., Liu, Y. (2014) Phytother. Res. 28, 498-509. ; Ming, L. G., Chen, K. M., Xian, C. J. (2013) J. Cell. Physiol. 228, 513-521. ; Feng, R., Feng, L., Yuan, Z., Wang, D., Wang, F., Tan, B., Han, S., Li, T., Li, D., Han, Y. (2013) Cell Biochem. Biophys. 67, 189-197. ; Hsieh, T. P., Sheu, S. Y., Sun, J. S., Chen, M. H. (2011) Phytomedicine 18, 176-185. ; Song, L., Zhao, J., Zhang, X., Li, H., Zhou, Y. (2013) Eur. J. Pharmacol. 714, 15-22. ; Ma, H. P., Ma, X. N., Ge, B. F., Zhen, P., Zhou, J., Gao, Y. H., Xian, C. J., Chen, K. M. (2014) Cell Prolif. 47, 527-539. ; St Laurent, G., Shtokalo, D., Tackett, M. R., Yang, Z., Eremina, T., Wahlestedt, C., Urcuqui-Inchima, S., Seilheimer, B., McCaffrey, T. A., Kapranov, P. (2012) BMC Genomics 13, 504. ; Mathy, N. W., Chen, X. M. (2017) J. Biol. Chem. 292, 12375-12382. ; Gibb, E. A., Brown, C. J., Lam, W. L. (2011) Mol. Cancer 10, 38. ; Lu, Y., Tang, L., Zhang, Z., Li, S., Liang, S., Ji, L., Yang, B., Liu, Y., Wei, W. (2018). Dis. Markers 2018, 6857042. ; Xiang, S., Li, Z., Weng, X. (2019) J. Cell. Biochem. 120, 18435-18445. ; Zhang, Y., Xu, R., Li, X., Tan, Q., Huang, P., Zhang, Y., Qin, M., Ren, L. (2019) Biosci. Rep. 39. ; Hao, L., Wang, J., Liu, N. (2019) J Cell Biochem 120, 12912-12923. ; Huang, J., Peng, J., Cao, G., Lu, S., Liu, L., Li, Z., Zhou, M., Feng, M., Shen, H. (2016) Cell. Physiol. Biochem. 39, 1177-1186. ; Li, L., Jiang, D. (2019) J. Cell. Biochem. 120, 16867-16875. ; Yelin, E., Weinstein, S., King, T. (2016) Semin. Arthritis Rheum. 46, 259-260. ; Bashir, J., Sherman, A., Lee, H., Kaplan, L., Hare, J. M. (2014) PM&R 6, 61-69. ; Woolf, A. D. (2015) BMC Musculoskeletal Disorders 16, Article S3. ; Xu, Z.-S., Wang, X.-Y., Xiao, D.-M., Hu, L.-F., Lu, M., Wu, Z.-Y., Bian, J.-S. (2011) Free Radic. Biol. Med. 50, 1314-1323. ; Seo, H.-J., Cho, Y.-E., Kim, T., Shin, H.-I., Kwun, I.-S. (2010) Nutr. Res. Pract. 4, 356-361. ; Fang, J., Zhang, Y. (2017) Front. Pharmacol. 8, 734. ; Sun, Z. B., Wang, J. W., Xiao, H., Zhang, Q. S., Kan, W. S., Mo, F. B., Hu, S., Ye, S. N. (2015) Osteoporos. Int. 26, 187-197. ; Zeng, R., Wang, X., Zhou, Q., Fu, X., Wu, Q., Lu, Y., Shi, J., Klaunig, J. E., Zhou, S. (2019) Toxicol. Appl. Pharmacol. 379, 114639. ; Huang, Z., Cheng, C., Cao, B., Wang, J., Wei, H., Liu, X., Han, Y., Yang, S., Wang, X. (2018) Cell. Physiol. Biochem. 47, 694-706. ; Xie, X., Pei, F., Wang, H., Tan, Z., Yang, Z., Kang, P. (2015) J. Biomater. Appl. 30, 290-299. ; Fatica, A., Bozzoni, I. (2014) Nat. Rev. Genet. 15, 7-21. ; Sheng, C., Hu, F., Wu, L. (2019) Eur. J. Pharmacol. 854, 28-38. ; Feldstein, O., Nizri, T., Doniger, T., Jacob, J., Rechavi, G., Ginsberg, D. (2013) Mol. Cancer 12, 131. ; Brodie, S., Lee, H. K., Jiang, W., Cazacu, S., Xiang, C., Poisson, L. M., Datta, I., Kalkanis, S., Ginsberg, D., Brodie, C. (2017) Oncotarget 8, 31785-31801. ; Hao, L., Wang, J., Liu, N. (2019) J. Cell. Biochem. 120, 12912-12923. ; Pan, L., Zhang, Y., Chen, N., Yang, L. (2017) Int. J. Mol. Sci. 18. ; Mumtaz, P. T., Bhat, S. A., Ahmad, S. M., Dar, M. A., Ahmed, R., Urwat, U., Ayaz, A., Shrivastava, D., Shah, R. A., Ganai, N. A. (2017) Biol. Proc. Online 19, 3. ; Markadieu, N., Rios, K., Spiller, B. W., McDonald, W. H., Welling, P. A., Delpire, E. (2014) J. Biol. Chem. 289, 29273-29284. ; Yan, Y., Laroui, H., Ingersoll, S. A., Ayyadurai, S., Charania, M., Yang, S., Dalmasso, G., Obertone, T. S., Nguyen, H., Sitaraman, S. V. (2011) J. Immunol. 187, 1496-1505. ; Yan, Y., Dalmasso, G., Nguyen, H. T., Obertone, T. S., Sitaraman, S. V., Merlin, D. (2009) PLoS One 4, e5049. ; Zhong, Z., Ye, S., Xiong, Y., Wu, L., Zhang, M., Fan, X., Li, L., Fu, Z., Wang, H., Chen, M., Yan, X., Huang, W., Ko, D. S., Wang, Y., Ye, Q. (2016) Transpl. Int. 29, 98-107. ; Mohyeldin, A., Garzon-Muvdi, T., Quinones-Hinojosa, A. (2010) Cell Stem Cell 7, 150-161. ; Sanghera, K. P., Mathalone, N., Baigi, R., Panov, E., Wang, D., Zhao, X., Hsu, H., Wang, H., Tropepe, V., Ward, M., Boyd, S. R. (2011) Mol. Cell. Neurosci. 47, 145-153. ; Hu, S., Zhang, Y., Zhang, M., Guo, Y., Yang, P., Zhang, S., Simsekyilmaz, S., Xu, J. F., Li, J., Xiang, X., Yu, Q., Wang, C. Y. (2016) Mol. Med. 21, 912-923. ; Zhou, H., Yuan, Y., Liu, Y., Deng, W., Zong, J., Bian, Z. Y., Dai, J., Tang, Q. Z. (2014) Exp. Ther. Med. 7, 1116-1122. ; Li, C., Liang, G., Yang, S., Sui, J., Yao, W., Shen, X., Zhang, Y., Peng, H., Hong, W., Xu, S., Wu, W., Ye, Y., Zhang, Z., Zhang, W., Yin, L., Pu, Y. (2017) Oncotarget 8, 93476-93491. ; Yao, X., Yan, C., Zhang, L., Li, Y., Wan, Q. (2018) Medicine (Baltimore) 97, e0473. Contributed Indexing: Keywords: PI3K/AKT/mTOR; SPAK/JNK; TALNEC2; hypoxia; icariin; osteonecrosis Substance Nomenclature: 0 (Ccnd1 protein, mouse) ; 0 (Cdkn2a protein, mouse) ; 0 (Cyclin-Dependent Kinase Inhibitor p16) ; 0 (Flavonoids) ; 0 (RNA, Long Noncoding) ; 0 (Trp53 protein, mouse) ; 0 (Tumor Suppressor Protein p53) ; 136601-57-5 (Cyclin D1) ; VNM47R2QSQ (icariin) Entry Date(s): Date Created: 20191218 Date Completed: 20210601 Latest Revision: 20210601 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Icariin alleviates hypoxia-induced damage in MC3T3-E1 cells by downregulating TALNEC2.